Author: admin

Collaboration with Fraunhofer SCAI

APTA Therapeutics is pleased to announce that it has entered into a collaboration with the Fraunhofer Institute for Algorithms and Scientific Computing (SCAI) to implement state-of-the-art data-and knowledge-driven methods to better define patient recruitment for the upcoming clinical trials in post-viral infectious diseases.

Prospective, explorative, randomized, controlled, double-blind, cross-over phase IIa clinical trial to investigate safety and tolerability as well as potential clinical effects of BC007 in patients with post-COVID syndrome.

The University Hospital of Erlangen recently completed a phase 2a investigator-initiated trial (reCOVer) of rovunaptabin in 30 patients with post-COVID syndrome (EudraCT 2022-001781-35). The study confirmed the safety and tolerability of rovunaptabin, with improvements in fatigue and post-exertional malaise (PEM) observed. Furthermore, MRIs and functional imaging revealed that resting brain activity normalised during rovunaptabin therapy, […]

The Persistence of Autoantibody Neutralisation by BC 007 in Patients With Chronic HFrEF and Autoantibodies Against the Beta1-Adrenergic Receptor.

In a recently completed randomised phase 2a clinical trial involving 30 subjects with heart failure (NCT04192214), treatment with rovunaptabin was found to be safe and well tolerated. Furthermore, the study showed promising improvements in cardiac performance, as measured by left ventricular ejection fraction (LVEF), in patients who received the treatment.Further clinical investigator-initiated trials are planned […]

Agreement with CIBIT

APTA Therapeutics is pleased to announce that it has entered into an agreement with Coimbra Institute for Biomedical Imaging and Translational Research (CIBIT) to support an Investigator Initiated Trial with rovunaptabin in patients with long COVID.